Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
07. November 2022 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
02. November 2022 06:30 ET
|
Surface Oncology, Inc.
– Two confirmed partial responses to SRF388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year –– Company focusing...
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
19. Oktober 2022 07:00 ET
|
Surface Oncology, Inc.
– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study elucidates how SRF388 binds to IL-27 to prevent interaction with the IL-27 receptor, inhibiting the...
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
14. September 2022 07:30 ET
|
Surface Oncology, Inc.
- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition - - Findings support the...
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
07. September 2022 16:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
24. August 2022 16:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022
03. August 2022 07:00 ET
|
Surface Oncology, Inc.
– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization – – Interim...
Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
01. August 2022 16:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Appoints Carsten Brunn to Board of Directors
29. Juni 2022 07:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma
20. Juni 2022 10:05 ET
|
Surface Oncology, Inc.
- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer - CAMBRIDGE, Mass., June 20, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq:...